Coherus BioSciences (NASDAQ:CHRS) Releases Earnings Results, Misses Estimates By $0.34 EPS

Coherus BioSciences (NASDAQ:CHRS) posted its quarterly earnings data on Monday. The biotechnology company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.34), Zacks reports.

Coherus BioSciences Stock Performance

Shares of NASDAQ:CHRS remained flat at $1.04 during trading on Monday. The stock had a trading volume of 3,534,134 shares, compared to its average volume of 1,917,392. The firm has a 50 day simple moving average of $1.25 and a 200-day simple moving average of $1.19. Coherus BioSciences has a fifty-two week low of $0.66 and a fifty-two week high of $2.64. The firm has a market cap of $120.53 million, a P/E ratio of -13.00 and a beta of 0.92.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on CHRS shares. Robert W. Baird upped their target price on shares of Coherus BioSciences from $4.00 to $6.00 and gave the stock an “outperform” rating in a research report on Thursday, December 5th. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Coherus BioSciences in a report on Thursday, January 23rd. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $5.38.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.